Renal Cancer - Results from #660

Inflammatory response-based prognostication and personalized therapy decisions in clear cell renal cell cancer to aid precision oncology. November 7, 2023

Renal Cell Cancer - Insights in Drug Resistance Mechanisms. November 7, 2023

Surgical Management and Oncologic Outcomes of Renal Cell Carcinoma and Inferior Vena Caval Thrombi with Aggressive Histologic Variants. November 7, 2023

Clinical Application of Digital and Computational Pathology in Renal Cell Carcinoma: A Systematic Review. November 6, 2023

Efficacy and safety of cryoablation for localized renal tumor as an alternative approach to partial nephrectomy. November 6, 2023

Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. November 3, 2023

Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma. November 3, 2023

The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non-clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database. November 2, 2023

Regulation of HHLA2 expression in kidney cancer and myeloid cells. November 2, 2023

The Metastasis Pattern of Renal Cell Carcinoma Is Influenced by Histologic Subtype, Grade, and Sarcomatoid Differentiation. November 1, 2023

Digital Spatial Profiling Identifies the Tumor Periphery as a Highly Active Biological Niche in Clear Cell Renal Cell Carcinoma. November 1, 2023

Early CRP kinetics to predict long-term efficacy of first-line immune-checkpoint inhibition combination therapies in metastatic renal cell carcinoma: an updated multicentre real-world experience applying different CRP kinetics definitions. October 31, 2023

Development of a novel score (RENSAFE) to determine probability of acute kidney injury and renal functional decline post surgery: A multicenter analysis. October 31, 2023

LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma. October 30, 2023

Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring. October 30, 2023

Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study. October 27, 2023

Clinical values of circulating tumor cells count in localized renal cell carcinoma. October 27, 2023

Multi-institutional Retrospective Validation and Comparison of the Simplified PADUA REnal Nephrometry System for the Prediction of Surgical Success of Robot-assisted Partial Nephrectomy. October 27, 2023

Simplified PADUA renal (SPARE) nephrometry score validation and long-term outcomes after robot-assisted partial nephrectomy. October 27, 2023

suPARnostic: an advanced predictive tool for detecting recurrence in renal cell carcinoma. October 26, 2023

Page 34 of 456